Status: Not yet recruiting
Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery
The investigators aim to compare the incidence rates of seroma (fluid collection) and hematoma (blood clot) following breast cancer surgery between the conventional non-steroidal anti-inflammatory drug (NSAID) Ketorolac and MAXIGESIC. The investigators seek to determine the complication rates in patients receiving MAXIGESIC post-surgery, hypothesizing that the higher dosage of ibuprofen in MAXIGESIC compared to Ketorolac will result in lower complication rates.
Participants needed: 60
Trial details
Age: 20-70Biological sex: FemaleType: ObservationalSponsor: Seoul National University HospitalUpdated: Sep 19, 2024Duration: 3 Months
Eligibility criteria
Systemic performance status 0-2 according to ECOG criteria [+5]
Patients undergoing immediate reconstruction operation [+2]